Penfluridol: a long-acting oral neuroleptic. A controlled study.
The clinical promise of penfluridol as a long-acting oral antipsychotic medication has led to a number of controlled studies designed to verify its usefulness. These studies have been reviewed and compared with a controlled study carried out by the authors. The data obtained from this study have tended to confirm the impression of previous investigators that penfluridol, administered in a dosage of 40 to 80 mg on a once-a-week basis in a single dose, compares favorably with the antipsychotic activity of those neuroleptics requiring administration on a daily basis.
D000328:Adult; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010395:Penfluridol / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy*; D013881:Thioridazine / Q000009:adverse effects / Q000627:therapeutic use
D010880:Piperidines; D010395:Penfluridol; D013881:Thioridazine